Live from the NIH registry
Studies recruiting near Fort Wayne right now
Top 25 of 116 recruiting studies, sorted by proximity — each links to its official registry page
Patient Specific Talus Spacer Post Approval Study
Avascular Necrosis of the Talus
N/A
Observational 50 participants sought
Fort Wayne Orthopedics — Fort Wayne, Indiana (3.0 mi)
· Sponsor: Paragon 28
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma
Phase 3
Interventional 880 participants sought
Parkview Regional Medical Center — Fort Wayne, Indiana (3.0 mi)
· Sponsor: NRG Oncology
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
Breast Cancer
Phase 3
Interventional 100 participants sought
Research Site — Fort Wayne, Indiana (3.0 mi)
· Sponsor: AstraZeneca
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
Phase 3
Interventional 49 participants sought
Study Site 101 — Fort Wayne, Indiana (3.0 mi)
· Sponsor: Grifols Biologicals, LLC
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Carcinoma, Non-Small-Cell Lung
Phase 2
Interventional 480 participants sought
Fort Wayne Medical Oncology and Hematology — Fort Wayne, Indiana (3.0 mi)
· Sponsor: Janssen Research & Development, LLC
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Anatomic Stage II Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
Phase 3
Interventional 1,295 participants sought
Parkview Regional Medical Center — Fort Wayne, Indiana (3.0 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Ovarian Cancer, Fallopian Tube Cancer
Phase 3
Interventional 770 participants sought
Parkview Research Center at Parkview Regional Medical Center ( Site 0003) — Fort Wayne, Indiana (3.0 mi)
· Sponsor: Merck Sharp & Dohme LLC
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Previously Treated Non-Small Cell Lung Cancer
Phase 2, Phase 3
Interventional 10,000 participants sought
Parkview Regional Medical Center — Fort Wayne, Indiana (3.0 mi)
· Sponsor: SWOG Cancer Research Network
Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement
Aortic Stenosis, Coronary Artery Disease
N/A
Interventional 4,000 participants sought
Parkview Research Center — Fort Wayne, Indiana (3.0 mi)
· Sponsor: University of British Columbia
A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH)
Idiopathic Hypersomnia
Phase 3
Interventional 248 participants sought
Fort Wayne Neurological Center — Fort Wayne, Indiana (3.0 mi)
· Sponsor: Harmony Biosciences Management, Inc.
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Metastatic Non-small Cell Lung Cancer
Phase 3
Interventional 734 participants sought
Parkview Packnett Family Cancer Institute — Fort Wayne, Indiana (3.0 mi)
· Sponsor: NovoCure GmbH
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Carcinoma, Transitional Cell, Urinary Bladder Neoplasms
Phase 3
Interventional 450 participants sought
Parkview Research Center at Parkview Regional Medical Center — Fort Wayne, Indiana (3.0 mi)
· Sponsor: Eli Lilly and Company
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7
Phase 2, Phase 3
Interventional 613 participants sought
Radiation Oncology Associates PC — Fort Wayne, Indiana (3.0 mi)
· Sponsor: National Cancer Institute (NCI)
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Phase 3
Interventional 582 participants sought
Research Site — Fort Wayne, Indiana (3.0 mi)
· Sponsor: AstraZeneca
A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)
Alzheimer Disease
Phase 4
Interventional 150 participants sought
NexGen Research — Fort Wayne, Indiana (3.0 mi)
· Sponsor: Alpha Cognition, Inc
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Phase 3
Interventional 700 participants sought
Parkview Research Center at Parkview Regional Medical Center — Fort Wayne, Indiana (3.0 mi)
· Sponsor: Eli Lilly and Company
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Multiple Myeloma
Phase 2, Phase 3
Interventional 680 participants sought
Fort Wayne Medical Oncology And Hematology /ID# 278141 — Fort Wayne, Indiana (3.0 mi)
· Sponsor: AbbVie
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Non Small Cell Lung Carcinoma, c-MET
Phase 1, Phase 2
Interventional 252 participants sought
Parkview Comprehensive Cancer Center /ID# 271879 — Fort Wayne, Indiana (3.0 mi)
· Sponsor: AbbVie
A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)
Heart Failure With Preserved Ejection Fraction
Phase 2
Interventional 90 participants sought
Local Institution - 26 — Fort Wayne, Indiana (3.0 mi)
· Sponsor: Edgewise Therapeutics, Inc.
Assessing Connected-Health, Pressure-Monitoring Technology for Improving Compression Therapy in Venous Leg Ulcer Treatment
Venous Leg Ulcers (VLUs)
N/A
Interventional 40 participants sought
Parkview Center for Wound Healing — Fort Wayne, Indiana (3.0 mi)
· Sponsor: Feeltect Limited
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer, c-MET
Phase 2, Phase 3
Interventional 490 participants sought
Parkview Research Center /ID# 277651 — Fort Wayne, Indiana (3.0 mi)
· Sponsor: AbbVie
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
B-cell Malignancy, Chronic Lymphocytic Leukemia
Phase 1
Interventional 120 participants sought
American Oncology Partners — Fort Wayne, Indiana (3.0 mi)
· Sponsor: Carna Biosciences, Inc.
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
Non Small Cell Lung Cancer
Phase 3
Interventional 630 participants sought
Fort Wayne Medical Oncology - 1133 — Fort Wayne, Indiana (3.0 mi)
· Sponsor: OncoC4, Inc.
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Colorectal Neoplasms
Phase 3
Interventional 1,000 participants sought
Fort Wayne Medical Oncology & Hematology — Fort Wayne, Indiana (3.0 mi)
· Sponsor: Janssen Research & Development, LLC
Prevail Global Study
Coronary Artery Disease
N/A
Interventional 1,205 participants sought
Parkview Health — Fort Wayne, Indiana (3.0 mi)
· Sponsor: Medtronic Vascular